Free Trial

PDS Biotechnology (PDSB) Competitors

PDS Biotechnology logo
$1.15 -0.05 (-4.17%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.43%)
As of 07/18/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDSB vs. FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, NBTX, PRQR, and SLRN

Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), ProQR Therapeutics (PRQR), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry.

PDS Biotechnology vs. Its Competitors

Adherex Technologies (NASDAQ:FENC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Adherex Technologies has higher revenue and earnings than PDS Biotechnology. Adherex Technologies is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$47.54M4.90-$440K-$0.51-16.55
PDS BiotechnologyN/AN/A-$37.61M-$0.94-1.22

Adherex Technologies has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

PDS Biotechnology has a net margin of 0.00% compared to Adherex Technologies' net margin of -45.52%. Adherex Technologies' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies-45.52% N/A -26.37%
PDS Biotechnology N/A -150.59%-69.15%

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 11.8% of Adherex Technologies shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Adherex Technologies had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Adherex Technologies and 0 mentions for PDS Biotechnology. Adherex Technologies' average media sentiment score of 0.75 beat PDS Biotechnology's score of -0.24 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Adherex Technologies Positive
PDS Biotechnology Neutral

Adherex Technologies presently has a consensus target price of $13.00, suggesting a potential upside of 54.03%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 682.61%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
PDS Biotechnology
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Summary

Adherex Technologies beats PDS Biotechnology on 10 of the 15 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PDSB vs. The Competition

MetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$54.85M$2.95B$5.55B$9.40B
Dividend YieldN/A2.47%3.75%4.03%
P/E Ratio-1.2219.7528.0119.82
Price / SalesN/A300.24432.8198.20
Price / CashN/A42.5936.1658.27
Price / Book2.257.678.125.65
Net Income-$37.61M-$55.28M$3.25B$257.91M
7 Day Performance-7.26%4.85%1.68%3.38%
1 Month Performance-28.57%11.70%7.30%11.11%
1 Year Performance-70.28%3.69%32.89%18.99%

PDS Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDSB
PDS Biotechnology
1.1693 of 5 stars
$1.15
-4.2%
$9.00
+682.6%
-70.2%$54.85MN/A-1.2220
FENC
Adherex Technologies
2.2781 of 5 stars
$8.47
-3.8%
$13.00
+53.5%
+33.1%$242.88M$47.54M-16.6110
VOR
Vor Biopharma
N/A$2.67
+39.8%
N/AN/A$238.67MN/A0.00140
INBX
Inhibrx Biosciences
3.0371 of 5 stars
$18.35
+12.4%
N/A+88.4%$236.39M$200K0.16166News Coverage
High Trading Volume
CGC
Canopy Growth
0.327 of 5 stars
$1.20
-6.3%
$2.00
+66.7%
-84.9%$235.35M$225.65M-0.303,150
LIMN
Liminatus Pharma
N/A$6.93
-23.2%
N/AN/A$234.65MN/A0.00N/AGap Up
ESPR
Esperion Therapeutics
3.9316 of 5 stars
$1.11
-5.1%
$7.00
+530.6%
-52.2%$231.89M$332.31M-1.39200
BTMD
biote
2.5948 of 5 stars
$3.99
-5.5%
$8.00
+100.5%
-48.7%$230.88M$197.19M6.54194Positive News
NBTX
Nanobiotix
1.8778 of 5 stars
$4.75
-2.5%
$8.00
+68.6%
-5.2%$229.54M$39.18M0.00100Gap Up
PRQR
ProQR Therapeutics
2.5992 of 5 stars
$2.14
-1.8%
$8.00
+273.8%
+25.6%$229.36M$20.46M-6.11180
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135

Related Companies and Tools


This page (NASDAQ:PDSB) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners